Diagnosis and therapy of multiple myeloma

키워드

참고문헌 (65)

1. Palumbo A, "Multiple myeloma", N Engl J Med, 364, pp.1046~1060 (2011)
2. "SEER cancer statistics review" (2010)[URL]
3. Kristinsson SY, "Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003", J Clin Oncol, 25, pp.1993~1999 (2007)
4. Brenner H, "Recent major improvement in long-term survival of younger patients with multiple myeloma", Blood, 111, pp.2521~2526 (2008)
5. Durie BG, "Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation", Hematol J, 4, pp.379~398 (2003)
6. Durie BG, "International uniform response criteria for multiple myeloma", Leukemia, 20, pp.1467~1473 (2006)
7. Kyle RA, "Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma", Leukemia, 23, pp.3~9 (2009)
8. Kyle RA, "Review of 1027 patients with newly diagnosed multiple myeloma", Mayo Clin Proc, 78, pp.21~33 (2003)
9. Eleutherakis-Papaiakovou V, "Renal failure in multiple myeloma: incidence, correlations, and prognostic signif icance", Leuk Lymphoma, 48, pp.337~341 (2007)
10. Birgegard G, "Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey", Eur J Haematol, 77, pp.378~386 (2006)
11. Nucci M, "Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents", Clin Infect Dis, 49, pp.1211~1225 (2009)
12. Dispenzieri A, "International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders", Leukemia, 23, pp.215~224 (2009)
13. Fonseca R, "International Myeloma Working Group molecular classif ication of multiple myeloma: spotlight review", Leukemia, 23, pp.2210~2221 (2009)
14. Terpos E, "Advances in imaging and the management of myeloma bone disease", J Clin Oncol, 29, pp.1907~1915 (2011)
15. Zamagni E, "A prospective comparison of 18F-f luorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma", Haematologica, 92, pp.50~55 (2007)
16. Dimopoulos M, "Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3", Blood, 117, pp.4701~4705 (2011)
17. Durie BG, "A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival", Cancer, 36, pp.842~854 (1975)
18. Greipp PR, "International staging system for multiple myeloma", J Clin Oncol, 23, pp.3412~3420 (2005)
19. Avet-Loiseau H, "Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project", Leukemia, 27, pp.711~717 (2013)
20. Snozek CL, "Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system", Leukemia, 22, pp.1933~1937 (2008)
21. Mulligan G, "Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib", Blood, 109, pp.3177~3188 (2007)
22. Shaughnessy JD Jr, "A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1", Blood, 109, pp.2276~2284 (2007)
23. Zamagni E, "Prognostic relevance of 18-F FDG PET", CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation, 2011, pp.118, 5989~5995
24. Kumar SK, "Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis", Am J Hematol, 83, pp.614~617 (2008)
25. Attal M, "Single versus double autologous stem-cell transplantation for multiple myeloma", N Engl J Med, 349, pp.2495~2502 (2003)
26. Cavo M, "Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study", J Clin Oncol, 25, pp.2434~2441 (2007)
27. Segeren CM, "Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study", Blood, 101, pp.2144~2151 (2003)
28. Goldschmidt H., "Single vs. double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trial", Haematologica, 90(1), pp.38~ (2005)
29. Barlogie B, "Long-term followup of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences", J Clin Oncol, 28, pp.1209~1214 (2010)
30. Harousseau JL, "The role of complete response in multiple myeloma", Blood, 114, pp.3139~3146 (2009)
31. Chanan-Khan AA, "Importance of achieving a complete response in multiple myeloma, and the impact of novel agents", J Clin Oncol, 28, pp.2612~2624 (2010)
32. Ladetto M, "Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma", J Clin Oncol, 28, pp.2077~2084 (2010)
33. Fermand JP, "Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34-enriched ABSC: results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM)", Hematol J, 4(1), pp.59~ (2003)
34. Rajkumar SV, "Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group", J Clin Oncol, 24, pp.431~436 (2006)
35. Lokhorst HM, "Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma", Haematologica, 93, pp.124~127 (2008)
36. Morgan GJ, "Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results", Haematologica, 97, pp.442~450 (2012)
37. Rajkumar SV, "Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial", Lancet Oncol, 11, pp.29~37 (2010)
38. Richardson PG, "Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma", Blood, 116, pp.679~686 (2010)
39. Kumar S, "Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma", Blood, 119, pp.4375~4382 (2012)
40. Kumar SK, "Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study", Leukemia, 24, pp.1350~1356 (2010)
41. Jagannath S, "Extended followup of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma", Br J Haematol, 146, pp.619~626 (2009)
42. Harousseau JL, "Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study", Haematologica, 91, pp.1498~1505 (2006)
43. Rosinol L, "Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stemcell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics", J Clin Oncol, 25, pp.4452~4458 (2007)
44. Harousseau JL, "Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial", J Clin Oncol, 28, pp.4621~4629 (2010)
45. Sonneveld P, "Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65", GMMGHD4 trial, 2012, pp.30, 2946~2955
46. Cavo M, "Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study", Lancet, 376, pp.2075~2085 (2010)
47. Reeder CB, "Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial", Leukemia, 23, pp.1337~1341 (2009)
48. Myeloma Trialists’ Collaborative Group, "Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials", J Clin Oncol, 16, pp.3832~3842 (1998)
49. Ludwig H, "Thalidomidedexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma", Blood, 113, pp.3435~3442 (2009)
50. Facon T, "Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial", Lancet, 370, pp.1209~1218 (2007)
51. Hulin C, "Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01", 01 trial, 2009, pp.27, 3664~3670
52. Beksac M, "Addition of thalidomide to oral melphalan", prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group, 2011, pp.86, 16~22
53. Waage A, "Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma", Blood, 116, pp.2010~2116 (2010)
54. Wijermans P, "Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study", J Clin Oncol, 28, pp.3160~3166 (2010)
55. Palumbo A, "Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial", Blood, 112, pp.3107~3114 (2008)
56. Fayers PM, "Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials", Blood, 118, pp.1239~1247 (2011)
57. Palumbo A, "Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials", Haematologica, 98, pp.87~94 (2013)
58. Morgan GJ, "Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation", Blood, 118, pp.1231~1238 (2011)
59. Palumbo A, "Continuous lenalidomide treatment for newly diagnosed multiple myeloma", N Engl J Med, 366, pp.1759~1769 (2012)
60. Kumar SK, "Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial", Am J Hematol, 86, pp.640~645 (2011)
61. San Miguel JF, "Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma", N Engl J Med, 359, pp.906~917 (2008)
62. Mateos MV, "Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial", J Clin Oncol, 28, pp.2259~2266 (2010)
63. Mateos MV, "Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial", Lancet Oncol, 11, pp.934~941 (2010)
64. Palumbo A, "Bortezomibmelphalan- prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial", J Clin Oncol, 28, pp.5101~5109 (2010)
65. Bringhen S, "Efficacy and safety of once-weekly bortezomib in multiple myeloma patients", Blood, 116, pp.4745~4753 (2010)

관련 논문AI추천